Profile data is unavailable for this security.
About the company
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
- Revenue in USD (TTM)0.00
- Net income in USD-97.68m
- Incorporated2019
- Employees111.00
- LocationStructure Therapeutics Inc611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO 94080United StatesUSA
- Websitehttps://structuretx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.55bn | 58.00 | 16.44 | 1.91 | 11.70 | 13.07 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.59bn | 1.55k | 34.79 | 0.8937 | 20.03 | 2.60 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
Tilray Brands Inc | 743.25m | -351.95m | 1.60bn | 1.60k | -- | 0.4563 | -- | 2.15 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.60bn | 652.00 | -- | 1.72 | 23.00 | 2.68 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Soleno Therapeutics Inc | 0.00 | -52.03m | 1.60bn | 33.00 | -- | 10.73 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.65bn | 246.00 | 12.53 | 3.20 | 10.17 | 2.67 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.69bn | 111.00 | -- | 3.92 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.69bn | 142.00 | -- | 3.34 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.69bn | 92.00 | -- | 3.16 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.72bn | 112.00 | -- | 3.51 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.78bn | 1.22k | -- | 1.66 | -- | 8.54 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.80bn | 124.00 | 12.50 | 3.21 | 11.06 | 5.72 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Inhibrx Inc | 1.78m | -271.16m | 1.81bn | 166.00 | -- | 147.69 | -- | 1,017.41 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Novavax Inc | 996.61m | -398.71m | 1.83bn | 1.54k | -- | -- | -- | 1.83 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.83bn | 267.00 | -- | 12.11 | -- | 11.48 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Dec 2023 | 4.37m | 9.38% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.99m | 8.56% |
Driehaus Capital Management LLCas of 31 Dec 2023 | 2.60m | 5.58% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 2.33m | 5.01% |
Federated Global Investment Management Corp.as of 31 Dec 2023 | 2.26m | 4.84% |
Adage Capital Management LPas of 31 Dec 2023 | 1.76m | 3.77% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.68m | 3.60% |
Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.44m | 3.10% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.31m | 2.82% |
Citadel Advisors LLCas of 31 Dec 2023 | 1.14m | 2.45% |